The growth inhibitory effect of Interferon was shown to be dose dependent by Gresser, studying mouse Interferon and L1210 leukaemia (Gresser et al., 1970) . Similar findings have subsequently been reported for the antiproliferative activity of human lymphoblastoid, leukocyte and fibroblast Interferons on human leukaemic myeloblasts in short-term liquid culture (Balkwill & Oliver, 1977; Lundgren et al., 1980) .
On the basis of these findings, clinical evaluation of human lymphoblastoid Interferon (IFN-a) was undertaken at St. Bartholomew's Hospital in patients with haematological malignancies. A Phase I study was performed to determine whether doses high enough to achieve serum levels known to be growth inhibitory to myeloblasts in vitro (Balkwill & Oliver, 1977) could be administered in vivo (Rohatiner et al., 1982) . This having been demonstrated, a Phase II study of high dose IFN-a, administered by continuous intravenous infusion was commenced in patients with acute myelogenous leukaemia (AML) (Rohatiner et al., 1983) . Myeloblasts from patients with AML who received IFN in these studies were cultured with different concentrations of IFN-a (Rohatiner et al., 1982; Rohatiner et al., 1983) . It can be seen that there was no correlation between the serum levels achieved and response or between the degree of growth inhibition in vitro and response. However, only patients in whom peak serum levels > 103unitsml-l were achieved showed any indication of response, which suggests that minimum serum levels of 103units ml-I are required for any antiproliferative activity in vivo. These results confirm that IFN has a dose dependent growth inhibitory effect on human leukaemic myeloblasts in short term liquid culture, 50% inhibition occurring at an IFN concentration of 103 units ml-1. This appears to be reversible, inactivation of the IFN by incubation with trypsin using the same liquid culture system having been shown to virtually abrogate the growth inhibitory effect (Balkwill & Oliver, 1977) .
In contrast to the findings with myeloblasts reported above, when normal bone marrow was cultured with IFN-a (Balkwill & Oliver, 1977) , thymidine incorporation was suppressed but the effect on cell survival was less marked.
There was no significant response to therapy in patients in whom serum levels < 103 units ml -were achieved during IFN therapy and even above this level the results were very disappointing.
It is clearly possible that higher concentrations of IFN might have greater antiproliferative activity both in vitro and in vivo. However, the achievement of higher serum levels for prolonged periods is associated with intolerable toxicity. It must therefore be concluded from both the in vitro and in vivo data that high dose infusion IFN therapy will not play a major part in the primary therapy of acute myelogenous leukaemia. Whether an alternative role will be found remains to be seen.
